Nano-X Imaging Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Für Nano-X Imaging wird ein Gewinn- und Umsatzwachstum von 41.9% bzw. 31.7% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 55.9% pro Jahr steigen soll.
Wichtige Informationen
41.9%
Wachstumsrate der Gewinne
55.85%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 17.2% |
| Wachstumsrate der Einnahmen | 31.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 17 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyseartikel • 21h
News Flash: 2 Analysts Think Nano-X Imaging Ltd. (NASDAQ:NNOX) Earnings Are Under Threat
Today is shaping up negative for Nano-X Imaging Ltd. ( NASDAQ:NNOX ) shareholders, with the analysts delivering a...
Narrative-Update • Sep 17
NNOX: New Latin American Distribution And Capital Raise Will Support Future Rebound
Analysts have trimmed their fair value estimate for Nano-X Imaging from $7.40 to $5.00. They now use slightly higher discount rates and assume more moderate revenue growth, partly offset by a small improvement in projected profit margins and a marginally lower future P/E ratio.
Narrative-Update • Jul 29
NNOX: New Peru Agreement Will Support Future Stock Upside Potential
Analysts have adjusted their Nano-X Imaging price target to reflect a fair value move from $5.00 to $3.00, citing updated expectations around revenue growth, profit margins, and assumptions about the future price-to-earnings (P/E) ratio. What’s in the News for Nano-X Imaging Nano-X Imaging issued preliminary unaudited revenue guidance for the second quarter of 2026, with expected revenue of approximately US$4.0 million to US$4.1 million compared with US$3.0 million for the same quarter in 2025.Narrative-Update • Jul 15
NNOX: Restructuring And Outsourced Production Will Drive Future Rebound Potential
Analysts have trimmed their price target on Nano-X Imaging by $2, reflecting updated assumptions for fair value at $7.4, a slightly higher discount rate of 8.58%, revised revenue growth expectations of 94.80%, a lower projected profit margin of 6.12%, and a higher future P/E of 122.52. What’s in the News for Nano-X Imaging Multiple law firms filed securities fraud class action lawsuits against Nano-X Imaging Ltd.
Narrative-Update • Jul 01
NNOX: Legal Overhang May Set Stage For Future Upside Repricing
Nano-X Imaging's analyst price target has been revised to $5.80 from $6.65. Analysts point to updated fair value estimates, a slightly higher discount rate, adjusted revenue growth assumptions, an updated profit margin outlook, and a lower future P/E multiple to support the change.Seeking Alpha • Jun 26
Nano-X Withdraws Guidance, Signals Rocky Road Ahead
Summary Nano-X Imaging Ltd. is downgraded to a sell as its narrative shifts from disruptive growth to execution and survival. NNOX's Q1 revenue rose 53% to $4.3M, but core Nanox.ARC hardware contributed minimally; most revenue stems from teleradiology and AI/Health IT. Withdrawn FY26 guidance, persistent cash burn, and explicit going concern warnings highlight severe liquidity and execution risks. Despite early commercial traction and partnerships, delayed deployments and a shrinking cash runway make near-term dilution highly likely. Read the full article on Seeking AlphaNarrative-Update • Jun 17
NNOX: New Distribution Agreements Will Support Future Stock Upside Potential
Analysts have reduced their Nano-X Imaging price target by $2 to reflect updated assumptions around long term revenue growth, profit margins, and future P/E multiples. What’s in the News for Nano-X Imaging Nano-X Imaging signed a U.S. distribution agreement through its subsidiary Nanox Impact Inc.Narrative-Update • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.Narrative-Update • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.Narrative-Update • Apr 12
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).Narrative-Update • Mar 28
NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.Narrative-Update • Mar 12
NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.Narrative-Update • Feb 25
NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).Narrative-Update • Feb 10
NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.Narrative-Update • Jan 27
NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).Narrative-Update • Jan 12
NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.Narrative-Update • Dec 26
NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.Narrative-Update • Dec 12
NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).Analyseartikel • Oct 31
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative-Update • Aug 15
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.Analyseartikel • May 27
Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
One thing we could say about the analysts on Nano-X Imaging Ltd. ( NASDAQ:NNOX ) - they aren't optimistic, having just...
Neues Narrative • Apr 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.Analyseartikel • Apr 01
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 14
Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Summary Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system. Expect Nano-X to reach inflection point for revenue growth due to FDA approvals and the huge need for cost-effective X-ray monitoring and analyzing solutions. Read the full article on Seeking AlphaSeeking Alpha • Jan 04
Nano-X Imaging's Recent Surge Is Undeserved
Summary Nano-X Imaging shares surged 50.8% in a month, but I maintain a "sell' rating due to overvaluation and poor fundamentals. Despite some positive developments, Nano-X generates minimal revenue, significant net losses, and cash outflows, necessitating future capital raises. Recent FDA clearances and accolades are promising, but there's no concrete evidence that their technologies will achieve commercial success. The company's declining net cash balance and unjustified valuation reinforce my bearish stance on Nano-X Imaging. Read the full article on Seeking AlphaAnalyseartikel • Dec 05
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Key Insights Nano-X Imaging to hold its Annual General Meeting on 10th of December Total pay for CEO Erez Meltzer...Analyseartikel • Nov 25
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Sep 29
Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Summary Nano-X Imaging has seen a significant decline in stock value, shedding over 37% since February, with no strong catalysts to reverse the trend. Nvidia’s small stake in Nano-X briefly boosted the stock, but without further investment or partnership, investor excitement has waned. Persistent financial losses, slow revenue growth, and limited global reach make Nano-X a high-risk investment with potential for further value erosion. Read the full article on Seeking AlphaAnalyseartikel • Apr 05
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 01
Nano-X Imaging: System Deployments Finally Begin
Summary Nano-X Imaging is executing its long-awaited roll-out strategy with multiple Nanox.ARC system deployments in the U.S. The company has also made progress in Africa and Latin America with installations and distribution agreements. However, financial performance is still lagging with scant details on how Nano-X will scale up to commercial scale. The story is improving, but there are still too many concerns for me to invest in NNOX stock. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 50 | -33 | N/A | N/A | 2 |
| 12/31/2027 | 41 | -34 | N/A | N/A | 2 |
| 12/31/2026 | 22 | -96 | N/A | -39 | 1 |
| 6/30/2026 | 16 | -117 | -52 | -47 | N/A |
| 3/31/2026 | 15 | -76 | -50 | -44 | N/A |
| 12/31/2025 | 13 | -75 | -45 | -41 | N/A |
| 9/30/2025 | 12 | -56 | -45 | -41 | N/A |
| 6/30/2025 | 12 | -56 | -42 | -38 | N/A |
| 3/31/2025 | 12 | -55 | -41 | -37 | N/A |
| 12/31/2024 | 11 | -54 | -39 | -37 | N/A |
| 9/30/2024 | 11 | -50 | -41 | -39 | N/A |
| 6/30/2024 | 10 | -57 | -44 | -42 | N/A |
| 3/31/2024 | 10 | -61 | -45 | -44 | N/A |
| 12/31/2023 | 10 | -61 | -48 | -45 | N/A |
| 9/30/2023 | 10 | -103 | -49 | -47 | N/A |
| 6/30/2023 | 10 | -101 | -45 | -42 | N/A |
| 3/31/2023 | 9 | -103 | -48 | -43 | N/A |
| 12/31/2022 | 9 | -113 | -51 | -43 | N/A |
| 9/30/2022 | 8 | -82 | -63 | -50 | N/A |
| 6/30/2022 | 5 | -77 | -65 | -49 | N/A |
| 3/31/2022 | 3 | -71 | -66 | -45 | N/A |
| 12/31/2021 | 1 | -62 | -61 | -38 | N/A |
| 9/30/2021 | N/A | -59 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -56 | N/A | N/A | N/A |
| 3/31/2021 | N/A | -49 | N/A | N/A | N/A |
| 12/31/2020 | N/A | -44 | -36 | -22 | N/A |
| 9/30/2020 | N/A | -44 | -13 | -12 | N/A |
| 6/30/2020 | N/A | -35 | -9 | -9 | N/A |
| 3/31/2020 | N/A | -29 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -23 | N/A | -6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NNOX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: NNOX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: NNOX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: NNOXDie Einnahmen des Unternehmens (31.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (13.6% pro Jahr).
Hohe Wachstumseinnahmen: NNOXDie Einnahmen des Unternehmens (31.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NNOX in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/21 07:20 |
| Aktienkurs zum Tagesende | 2026/09/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Nano-X Imaging Ltd. wird von 8 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Scott Henry | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Ravi Misra | Berenberg |